NASDAQ · Biotechnology

ANNX (ANNX) Stock

$5.37 +0.75% NASDAQ: ANNX Healthcare

Valuation

MetricValue
Price$5.37
Market Cap$879.83M
P/E Ratio-3.71
P/B Ratio2.80
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$7.18
52-Week Low$1.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-97.64%
ROA-74.46%
ROCE-101.89%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.12
Current Ratio5.63

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-131.0M$-146.0M$-144.0M$-154.0M$-216.0M
Net Profit$-130.0M$-142.0M$-134.0M$-138.0M$-207.0M
EPS$-3.34$-2.60$-1.77$-1.01$-1.34
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$287.0M$285.0M$298.0M$350.0M$278.0M
Total Liabilities$55.0M$54.0M$47.0M$57.0M$66.0M
Cash$75.0M$140.0M$225.0M$49.0M$162.0M
Borrowings$35.0M$33.0M$31.0M$29.0M$26.0M

Latest News

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 GlobeNewswire · Jul 14, 2026 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jun 16, 2026 Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead MarketBeat · Jun 9, 2026 Exploring 3 High Growth Tech Stocks in the US Market Simply Wall St. · Jun 9, 2026 Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout MarketBeat · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-106.0M$-116.0M$-121.0M$-118.0M$-186.0M
Investing Cash Flow$-90.0M$52.0M$71.0M$-219.0M$190.0M
Financing Cash Flow$0$-8.0M$0$-1.0M$0
Net Cash Flow$-194.0M$65.0M$85.0M$-176.0M$113.0M
Free Cash Flow$-108.0M$-123.0M$-121.0M$-118.0M$-186.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-28.98%
Quick Ratio6.35
Interest Coverage—
Return 1Y113.71%
Return 3Y61.59%
Return 5Y-75.26%

Ownership

Insiders Held0.49%
Institutions Held102.39%
Institutions Float Held102.90%
Institutional HolderSharesReport Date
Redmile Group, LLC14,549,7682026-03-31
Blackrock Inc.10,938,5092026-03-31
FMR, LLC10,635,6482026-03-31
BVF Inc.8,698,1732026-03-31
State Street Corporation6,919,2552026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
AURA $7.06 -1.40% -4.35 $453.25M 0.00%
DBVTDBV Technologies S.A. $15.84 +0.83% -3.27 $378.92M 0.00%
DMAC $6.65 -1.27% -8.09 $358.56M 0.00%

About ANNX

ANNX is led by CEO Douglas E. Love, employs 106 people, headquartered in US, publicly traded since 2020.

ANNX stock trades at $5.37 with a market capitalization of $879.83M. The stock is valued at a price-to-earnings (P/E) ratio of -3.71, price-to-book of 2.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.85 and $7.18, and currently trades 25.2% below its 52-week high.

On profitability, ANNX generates a return on equity (ROE) of -97.64%, return on capital employed of -101.89%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides